The FDA advisory committee gave a green light last week for boosters to those over 65, and people at “high-risk” if they had received two Pfizer doses before. Besides the decision itself, I was struck by how our evaluation is skewed by what we think we’re doing with these approvals: protecting the individual, protecting public health, fighting the pande…